1
|
Riccio G, Bottone S, La Regina G, Badolati N, Passacantilli S, Rossi GB, Accardo A, Dentice M, Silvestri R, Novellino E, Stornaiuolo M. A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist. Biochemistry 2018; 57:839-851. [DOI: 10.1021/acs.biochem.7b01087] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Gennaro Riccio
- Department
of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Sara Bottone
- Department
of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Giuseppe La Regina
- Istituto
Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie
del Farmaco, Sapienza University of Rome, Rome, Italy
| | - Nadia Badolati
- Department
of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Sara Passacantilli
- Istituto
Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie
del Farmaco, Sapienza University of Rome, Rome, Italy
| | - Giovanni Battista Rossi
- Gastroenterology
and gastrointestinal endoscopy unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy
| | - Antonella Accardo
- Department
of Pharmacy, University of Naples Federico II, Naples, Italy
| | - Monica Dentice
- Department
of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Romano Silvestri
- Istituto
Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie
del Farmaco, Sapienza University of Rome, Rome, Italy
| | - Ettore Novellino
- Department
of Pharmacy, University of Naples Federico II, Naples, Italy
| | | |
Collapse
|
2
|
La Regina G, Bai R, Coluccia A, Famiglini V, Passacantilli S, Naccarato V, Ortar G, Mazzoccoli C, Ruggieri V, Agriesti F, Piccoli C, Tataranni T, Nalli M, Brancale A, Vultaggio S, Mercurio C, Varasi M, Saponaro C, Sergio S, Maffia M, Coluccia AML, Hamel E, Silvestri R. 3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin. ACS Med Chem Lett 2017; 8:521-526. [PMID: 28523104 DOI: 10.1021/acsmedchemlett.7b00022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Accepted: 04/26/2017] [Indexed: 11/28/2022] Open
Abstract
We designed 3-aroyl-1,4-diarylpyrrole (ARDAP) derivatives as potential anticancer agents having different substituents at the 1- or 4-phenyl ring. ARDAP compounds exhibited potent inhibition of tubulin polymerization, binding of colchicine to tubulin, and cancer cell growth. ARDAP derivative 10 inhibited the proliferation of BCR/ABL-expressing KU812 and LAMA84 cells from chronic myeloid leukemia (CML) patients in blast crisis and of hematopoietic cells ectopically expressing the imatinib mesylate (IM)-sensitive KBM5-WT or its IM-resistant KBM5-T315I mutation. Compound 10 minimally affected the proliferation of normal blood cells, indicating that it may be a promising agent to overcome broad tyrosine kinase inhibitor resistance in relapsed/refractory CML patients. Compound 10 significantly decreased CML proliferation by inducing G2/M phase arrest and apoptosis via a mitochondria-dependent pathway. ARDAP 10 augmented the cytotoxic effects of IM in human CML cells. Compound 10 represents a robust lead compound to develop tubulin inhibitors with potential as novel treatments for CML.
Collapse
Affiliation(s)
- Giuseppe La Regina
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Ruoli Bai
- Screening
Technologies Branch, Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, Frederick National Laboratory for
Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States
| | - Antonio Coluccia
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Valeria Famiglini
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Sara Passacantilli
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Valentina Naccarato
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Giorgio Ortar
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Carmela Mazzoccoli
- Laboratory
of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
| | - Vitalba Ruggieri
- Laboratory
of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
| | - Francesca Agriesti
- Laboratory
of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
| | - Claudia Piccoli
- Laboratory
of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
- Department
of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy
| | - Tiziana Tataranni
- Laboratory
of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
| | - Marianna Nalli
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Andrea Brancale
- Cardiff
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB, U.K
| | - Stefania Vultaggio
- Experimental
Therapeutics Unit, IFOM-the FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, I-20139 Milano, Italy
| | - Ciro Mercurio
- Experimental
Therapeutics Unit, IFOM-the FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, I-20139 Milano, Italy
| | - Mario Varasi
- Experimental
Therapeutics Unit, IFOM-the FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, I-20139 Milano, Italy
| | - Concetta Saponaro
- Clinical
Proteomics, Polo Oncologico Giovanni Paolo II, ASL−University of Salento, Piazza Muratore 1, 73100 Lecce, Italy
| | - Sara Sergio
- Clinical
Proteomics, Polo Oncologico Giovanni Paolo II, ASL−University of Salento, Piazza Muratore 1, 73100 Lecce, Italy
| | - Michele Maffia
- Clinical
Proteomics, Polo Oncologico Giovanni Paolo II, ASL−University of Salento, Piazza Muratore 1, 73100 Lecce, Italy
| | - Addolorata Maria Luce Coluccia
- Clinical
Proteomics, Polo Oncologico Giovanni Paolo II, ASL−University of Salento, Piazza Muratore 1, 73100 Lecce, Italy
| | - Ernest Hamel
- Screening
Technologies Branch, Developmental Therapeutics Program, Division
of Cancer Treatment and Diagnosis, Frederick National Laboratory for
Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States
| | - Romano Silvestri
- Institut
Pasteur Italy−Cenci Bolognetti Foundation, Dipartimento di
Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| |
Collapse
|
3
|
Coluccia A, Passacantilli S, Famiglini V, Sabatino M, Patsilinakos A, Ragno R, Mazzoccoli C, Sisinni L, Okuno A, Takikawa O, Silvestri R, La Regina G. New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation. J Med Chem 2016; 59:9760-9773. [PMID: 27690429 DOI: 10.1021/acs.jmedchem.6b00718] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy. Herein, we report a virtual screening study which led to the identification of compound 5 as a new IDO1 inhibitor. In order to improve the biological activity of the identified hit, arylthioindoles 6-30 were synthesized and tested. Among these, derivative 21 exhibited an IC50 value of 7 μM, being the most active compound of the series. Furthermore, compounds 5 and 21 induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29. Three-dimensional quantitative structure-activity relationship studies were carried out in order to rationalize obtained results and suggest new chemical modifications.
Collapse
Affiliation(s)
| | | | | | | | | | - Rino Ragno
- Alchemical Dynamics s.r.l. , Piazzale Aldo Moro 5, I-00185 Rome, Italy
| | - Carmela Mazzoccoli
- Laboratorio di Ricerca Pre-Clinica e Traslazionale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico della Basilicata (CROB) , Via Padre Pio 1, I-85028 Rionero in Vulture, Italy
| | - Lorenza Sisinni
- Laboratorio di Ricerca Pre-Clinica e Traslazionale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico della Basilicata (CROB) , Via Padre Pio 1, I-85028 Rionero in Vulture, Italy
| | - Alato Okuno
- National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology 35 Gengo, Morioka, Obu, Aichi 474-8511, Japan
| | - Osamu Takikawa
- National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology 35 Gengo, Morioka, Obu, Aichi 474-8511, Japan
| | | | | |
Collapse
|
4
|
La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio G, Hamel E, Lavia P, Silvestri R. New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. J Med Chem 2015; 58:5789-807. [PMID: 26132075 DOI: 10.1021/acs.jmedchem.5b00310] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
We designed 39 new 2-phenylindole derivatives as potential anticancer agents bearing the 3,4,5-trimethoxyphenyl moiety with a sulfur, ketone, or methylene bridging group at position 3 of the indole and with halogen or methoxy substituent(s) at positions 4-7. Compounds 33 and 44 strongly inhibited the growth of the P-glycoprotein-overexpressing multi-drug-resistant cell lines NCI/ADR-RES and Messa/Dx5. At 10 nM, 33 and 44 stimulated the cytotoxic activity of NK cells. At 20-50 nM, 33 and 44 arrested >80% of HeLa cells in the G2/M phase of the cell cycle, with stable arrest of mitotic progression. Cell cycle arrest was followed by cell death. Indoles 33, 44, and 81 showed strong inhibition of the SAG-induced Hedgehog signaling activation in NIH3T3 Shh-Light II cells with IC50 values of 19, 72, and 38 nM, respectively. Compounds of this class potently inhibited tubulin polymerization and cancer cell growth, including stimulation of natural killer cell cytotoxic activity and repression of Hedgehog-dependent cancer.
Collapse
Affiliation(s)
- Giuseppe La Regina
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Ruoli Bai
- ‡Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States
| | - Antonio Coluccia
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Valeria Famiglini
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Sveva Pelliccia
- §Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, I-80131 Napoli, Italy
| | - Sara Passacantilli
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Carmela Mazzoccoli
- ∥Laboratorio di Ricerca Pre-Clinica e Traslazionale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico della Basilicata, Via Padre Pio 1, I-85028 Rionero in Vulture, Italy
| | - Vitalba Ruggieri
- ∥Laboratorio di Ricerca Pre-Clinica e Traslazionale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico della Basilicata, Via Padre Pio 1, I-85028 Rionero in Vulture, Italy
| | - Annalisa Verrico
- ⊥Institute of Molecular Biology and Pathology, Sapienza Università di Roma, Consiglio Nazionale delle Ricerche (CNR), Via degli Apuli 4, I-00185 Roma, Italy
| | - Andrea Miele
- ⊥Institute of Molecular Biology and Pathology, Sapienza Università di Roma, Consiglio Nazionale delle Ricerche (CNR), Via degli Apuli 4, I-00185 Roma, Italy
| | - Ludovica Monti
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Marianna Nalli
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | - Romina Alfonsi
- #Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma, Viale Regina Elena 291, I-00161 Roma, Italy
| | - Lucia Di Marcotullio
- #Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma, Viale Regina Elena 291, I-00161 Roma, Italy.,∇Center for Life NanoScience@Sapienza, Istituto Italiano di Tecnologia, Viale Regina Elena 291, I-00161 Roma, Italy
| | - Alberto Gulino
- #Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma, Viale Regina Elena 291, I-00161 Roma, Italy
| | - Biancamaria Ricci
- #Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma, Viale Regina Elena 291, I-00161 Roma, Italy
| | - Alessandra Soriani
- #Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma, Viale Regina Elena 291, I-00161 Roma, Italy
| | - Angela Santoni
- ⊥Institute of Molecular Biology and Pathology, Sapienza Università di Roma, Consiglio Nazionale delle Ricerche (CNR), Via degli Apuli 4, I-00185 Roma, Italy.,#Department of Molecular Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Università di Roma, Viale Regina Elena 291, I-00161 Roma, Italy
| | - Michele Caraglia
- ○Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Via S.M. Costantinopoli 16, I-80138 Naples, Italy
| | - Stefania Porto
- ○Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Via S.M. Costantinopoli 16, I-80138 Naples, Italy
| | - Eleonora Da Pozzo
- ◆Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, I-56126 Pisa, Italy
| | - Claudia Martini
- ◆Department of Pharmacy, University of Pisa, Via Bonanno Pisano 6, I-56126 Pisa, Italy
| | - Andrea Brancale
- ¶Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, United Kingdom
| | - Luciana Marinelli
- §Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, I-80131 Napoli, Italy
| | - Ettore Novellino
- §Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, I-80131 Napoli, Italy
| | | | - Mario Varasi
- △European Institute of Oncology, Via Adamello 16, I-20139 Milano, Italy
| | - Ciro Mercurio
- ☆DAC SRL, Genextra Group, Via Adamello 16, I-20139 Milano, Italy
| | - Chiara Bigogno
- ▲APHAD Srl, Via della Resistanza 65, I-20090 Buccinasco, Italy
| | - Giulio Dondio
- ▲APHAD Srl, Via della Resistanza 65, I-20090 Buccinasco, Italy
| | - Ernest Hamel
- ‡Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States
| | - Patrizia Lavia
- ⊥Institute of Molecular Biology and Pathology, Sapienza Università di Roma, Consiglio Nazionale delle Ricerche (CNR), Via degli Apuli 4, I-00185 Roma, Italy
| | - Romano Silvestri
- †Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy
| |
Collapse
|
5
|
Stornaiuolo M, La Regina G, Passacantilli S, Grassia G, Coluccia A, La Pietra V, Giustiniano M, Cassese H, Di Maro S, Brancaccio D, Taliani S, Ialenti A, Silvestri R, Martini C, Novellino E, Marinelli L. Structure-Based Lead Optimization and Biological Evaluation of BAX Direct Activators as Novel Potential Anticancer Agents. J Med Chem 2015; 58:2135-48. [DOI: 10.1021/jm501123r] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Mariano Stornaiuolo
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Giuseppe La Regina
- Istituto
Pasteur—Fondazione Cenci Bolognetti, Dipartimento di Chimica
e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo
Moro 5, I-00185 Roma, Italy
| | - Sara Passacantilli
- Istituto
Pasteur—Fondazione Cenci Bolognetti, Dipartimento di Chimica
e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo
Moro 5, I-00185 Roma, Italy
| | - Gianluca Grassia
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Antonio Coluccia
- Istituto
Pasteur—Fondazione Cenci Bolognetti, Dipartimento di Chimica
e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo
Moro 5, I-00185 Roma, Italy
| | - Valeria La Pietra
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Mariateresa Giustiniano
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Hilde Cassese
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Salvatore Di Maro
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Diego Brancaccio
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Sabrina Taliani
- Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy
| | - Armando Ialenti
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Romano Silvestri
- Istituto
Pasteur—Fondazione Cenci Bolognetti, Dipartimento di Chimica
e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo
Moro 5, I-00185 Roma, Italy
| | - Claudia Martini
- Dipartimento
di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy
| | - Ettore Novellino
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| | - Luciana Marinelli
- Dipartimento
di Farmacia, Università di Napoli “Federico II”, via D. Montesano 49, 80131 Naples, Italy
| |
Collapse
|
6
|
La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R. New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. J Med Chem 2014; 57:6531-52. [PMID: 25025991 DOI: 10.1021/jm500561a] [Citation(s) in RCA: 64] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We synthesized 3-aroyl-1-arylpyrrole (ARAP) derivatives as potential anticancer agents having different substituents at the pendant 1-phenyl ring. Both the 1-phenyl ring and 3-(3,4,5-trimethoxyphenyl)carbonyl moieties were mandatory to achieve potent inhibition of tubulin polymerization, binding of colchicine to tubulin, and cancer cell growth. ARAP 22 showed strong inhibition of the P-glycoprotein-overexpressing NCI-ADR-RES and Messa/Dx5MDR cell lines. Compounds 22 and 27 suppressed in vitro the Hedgehog signaling pathway, strongly reducing luciferase activity in SAG treated NIH3T3 Shh-Light II cells, and inhibited the growth of medulloblastoma D283 cells at nanomolar concentrations. ARAPs 22 and 27 represent a new potent class of tubulin polymerization and cancer cell growth inhibitors with the potential to inhibit the Hedgehog signaling pathway.
Collapse
Affiliation(s)
- Giuseppe La Regina
- Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma , Piazzale Aldo Moro 5, I-00185 Roma, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
La Regina G, Famiglini V, Passacantilli S, Pelliccia S, Punzi P, Silvestri R. A New, Simple, and High-Yielding Synthesis of 2,9-Dihydro-1H-pyrido[3,4-b]indol-1-ones. SYNTHESIS-STUTTGART 2014. [DOI: 10.1055/s-0033-1339155] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Giuseppe La Regina
- Istituto Pasteur - Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma
| | - Valeria Famiglini
- Istituto Pasteur - Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma
| | - Sara Passacantilli
- Istituto Pasteur - Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma
| | | | | | - Romano Silvestri
- Istituto Pasteur - Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma
| |
Collapse
|